COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off Science and Technology Print & eBook bundle options. Terms & conditions.
Equitable Access to High-Cost Pharmaceuticals - 1st Edition - ISBN: 9780128119457, 9780128119624

Equitable Access to High-Cost Pharmaceuticals

1st Edition

0.0 star rating Write a review
Editor: Zaheer-Ud-Din Babar
Paperback ISBN: 9780128119457
eBook ISBN: 9780128119624
Imprint: Academic Press
Published Date: 21st February 2018
Page Count: 238
Sales tax will be calculated at check-out Price includes VAT/GST
119.00
150.00
105.00
138.00
209.94
Unavailable
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Description

Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines.

Key Features

  • Evaluates impact and efficacy of current access policies and pricing regulation of high-cost drugs
  • Incorporates existing guidelines and recommendations by international organizations
  • Compares and contrasts how different countries fund and police high-cost drug access
  • Explores novel and emergent policies, including managed entry agreement, analysis of real world data and differential pricing
  • Reviews novel pharmaceuticals of current research interest

Readership

Pharmacoeconomics, health economics, pharmacy, public health and health administration professionals. Policymakers and funding bodies. Pharmaceutical research and insurance staff working across pricing, market access, policy and marketing. Some graduate and 1st year PhD students studying pharmacoeconomics, pharmacy and health economics

Table of Contents

1. Access to High Cost Medicines: An Overview
2. Health Technology Assessment
3. High-Cost Medicines in England
4. Managed Entry Agreements and High Cost Medicines (European Perspective)
5. Setting a Public Health Agenda to Support Access to High-Cost Medicines
6. Human Rights and Intellectual Property for Universal Access to New Essential Medicines
7. Access to High Price Medicines in Portugal
8. Improving Access to High-Cost Medicines in Low Income Countries in Africa: Creating a Functioning Pharmaceutical System in Uganda
9. Equitable Access to Biosimilars: An Overview
10. Access to High-Cost Medicines in Europe
11. Access to High-Cost Medicines in Australia
12. Access to High-Cost Medicines in New Zealand
13. Access to High-Cost Medicines in Wales

Details

No. of pages:
238
Language:
English
Copyright:
© Academic Press 2018
Published:
21st February 2018
Imprint:
Academic Press
Paperback ISBN:
9780128119457
eBook ISBN:
9780128119624

About the Editor

Zaheer-Ud-Din Babar

Professor Zaheer-Ud-Din Babar is a pharmacist by training, Prof Babar is the recipient of the prestigious “Research Excellence Award” from the University of Auckland. He understands the health systems and pharmacy globally and is known for his work in pharmaceutical policy and practice, including quality use of medicines, access to medicines, medicine prices and issues related to pharmacoeconomics. He has published in high impact journals such as PLoS Medicine and Lancet and has acted as a consultant for World Health Organization, Royal Pharmaceutical Society, Health Action International, International Union Against Tuberculosis and Lung Disease, World Bank, International Pharmaceutical Federation (FIP) and for the Pharmaceutical Management Agency of New Zealand.

Affiliations and Expertise

Professor Zaheer-Ud-Din Babar is the Professor in Medicines and Healthcare and the Director of the Centre of Pharmaceutical Policy and Practice Research at the University of Huddersfield, United Kingdom

Reviews

"Equitable Access to High-Cost Pharmaceuticals forms an all-inclusive source of knowledge for understanding the issues surrounding access to and cost of new medicines by merging theory with practice, providing a comprehensive outlook on pharmaceutical policy and regulation challenges." --Aris Angelis, The London School of Economics and Political Science

Ratings and Reviews